Navigation Links
Exelixis Announces Third Quarter 2007 Financial Results and Business Update
Date:11/5/2007

tended by one year our research collaboration with Bristol-Myers

Squibb (BMS) to develop and commercialize novel therapies targeted

against the Liver X Receptor. As a result of the extension, we expect

to receive additional research funding in the amount of $7.5 million.

BMS also has the option to extend the collaboration by an additional

year.

* Our wholly-owned subsidiaries Exelixis Plant Sciences, Inc. and

Agrinomics, LLC entered into a transaction with Agrigenetics, Inc., a

wholly-owned subsidiary of The Dow Chemical Company, which included

the sale of tangible and intangible assets and a research funding

agreement focused on the development of new tools for gene discovery

and validation of novel crop traits.

* We closed a public equity offering of seven million shares of common

stock, with net proceeds of approximately $71.9 million, after

deducting offering expenses.

Recent Developments

We presented phase 2 data for XL647 and XL880, and phase 1 data for XL184, XL765 and XL147 at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco. In total, 13 abstracts were accepted for poster presentation at the conference, reporting data from clinical trials or preclinical studies of XL880, XL647, XL184, XL147, XL765, XL820, XL844 and XL518.

We also announced that a recently completed phase 2 trial of XL784 did not meet its primary endpoint of reducing proteinuria compared with placebo in patients with proteinuria associated with diabetic nephropathy. Various subgroup analyses suggest that the compound may have potential to benefit patients with this disease. We submitted the XL784 data report to GSK on October 22, 2007 and GSK has 90 days from the date of submission of the data report to determine whether it will select XL784 for further clinical development and
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Pomerantz LLP is investigating claims on behalf of investors ... IPXL).  Such investors are advised to contact Robert ... ext. 237. The investigation concerns whether Impax ... Sections 10(b) and 20(a) of the Securities Exchange Act ... Impax Laboratories, Inc. (the "Company") issued a press release ...
(Date:7/29/2014)... 2014 A new report by ... applications and geography) - Size, Share, Global Trends, Company ... Forecast, 2013 - 2020", suggests that the global surgical ... 2020 registering a CAGR of 11.1% from 2014 to ... the electro surgical devices in operative procedures by providing ...
(Date:7/29/2014)... 2014 Philadelphia’s newest entrepreneurial incubation space is ... start. The Innovation Center @3401 , a collaborative effort ... Science Center to help attract and nurture start-up businesses ... 28. , The Innovation Center @3401 (ic@3401), ... Streets, is the new home of DreamIt Ventures ...
(Date:7/29/2014)... Md., July 29, 2014  United Therapeutics Corporation ... its financial results for the second quarter ... growth shows that our medicines are reaching ... arterial hypertension (PAH)," said Martine Rothblatt, Ph.D., ... "The commercial launch this quarter of our ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 3Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13
... 3 VIA Pharmaceuticals,(Nasdaq: VIAP ), a ... the treatment of cardiovascular disease, announced today that,Lawrence ... of VIA, and,James G. Stewart, senior vice president ... at the Seventh Annual Needham & Company,Biotechnology and ...
... Cynosure, Inc.,(Nasdaq: CYNO ), a leading developer ... systems, today announced that President and,Chief Executive Officer Michael ... company,s business outlook, growth strategy and,recent financial results at ... On Thursday, June 12, the company will present at ...
... 3 Masimo Corporation,(Nasdaq: MASI ), the ... announced,that it is scheduled to present at the ... Ritz Carlton, Laguna Nigel, in Dana Point, CA,on ... Joe E. Kiani, Chairman and,CEO, will be presenting., ...
Cached Biology Technology:Cynosure Announces Schedule of Upcoming Investor Conferences 2Masimo to Present at Goldman Sachs 29th Annual Global Healthcare Conference 2
(Date:7/28/2014)... MIT professor John Essigmann and colleagues from the University of ... thought if they could induce the virus to mutate uncontrollably, ... a strategy that our immune system uses against many ... caused HIV to mutate at an enhanced rate, as expected. ... a small clinical trial reported in 2011. In a new ...
(Date:7/28/2014)... brain cells suggests that the effects of a commonly ... are temporary. , The study, published in this week,s ... conducted by biologists at the University of California, San ... in response to concerns, arising from multiple studies on ... general anesthetics may increase their susceptibility to long-term cognitive ...
(Date:7/28/2014)... of the top 10 U.S. cities that have seen ... inconveniences as frequent road closures, overwhelmed storm drains and ... new NOAA technical report. , This nuisance flooding, caused ... U.S. coasts, between 300 and 925 percent since the ... Flood Frequency Changes around the United States, also finds ...
Breaking Biology News(10 mins):Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3
... difference between a lifeless sack of chemicals and ... they're organized, according to Stanford biophysical chemist Steven ... California-Davis and Lawrence Livermore National Laboratory, he has ... unprecedented resolution-on the order of 100 nanometers, a ...
... million grant from the National Cancer Institute, a Wake Forest ... the effectiveness of a drug that he developed for the ... M.D., Ph.D., pioneered a method to destroy cells of glioblastoma ... is currently being tested in clinical trials and Debinski is ...
... plumage, flamingos are a curiosity of nature. Now a new ... anatomical oddity that helps flamingos eat: erectile tissue. , Flamingos ... shallow water, they bend their necks, tilt their bills upside ... Their large tongue acts like a piston, sucking water into ...
Cached Biology News:With record resolution and sensitivity, tool images how life organizes in a cell membrane 2With record resolution and sensitivity, tool images how life organizes in a cell membrane 3With record resolution and sensitivity, tool images how life organizes in a cell membrane 4With record resolution and sensitivity, tool images how life organizes in a cell membrane 5With record resolution and sensitivity, tool images how life organizes in a cell membrane 6Scientist works to improve treatment for brain tumors 2Ohio University researchers discover evolutionary oddity in flamingos 2
...
BD BioCoat Poly-D-Lysine/Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine and laminin....
BD BioCoat Gelatin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of gelatin....
... internal standard for the quantification of 5-OxoETE ... is a polyunsaturated keto acid formed by ... It stimulates cytosolic calcium levels in neutrophils ... selectively stimulates the migration and degranulation of ...
Biology Products: